Home > Journals > Minerva Stomatologica > Past Issues > Minerva Stomatologica 2008 April;57(4) > Minerva Stomatologica 2008 April;57(4):189-98

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA STOMATOLOGICA

A Journal on Dentistry and Maxillofacial Surgery


Official Journal of the Italian Society of Odontostomatology and Maxillofacial Surgery
Indexed/Abstracted in: CAB, EMBASE, Index to Dental Literature, PubMed/MEDLINE, Scopus, Emerging Sources Citation Index


eTOC

 

ORIGINAL ARTICLES  


Minerva Stomatologica 2008 April;57(4):189-98

language: English, Italian

Osteo-promoting activity of OSTEOPLANT® ANGIOSTAD in vitro

Bellone G,, Scirelli T., Emanuelli G.

Department of Clinical Physiopathology University of Turin, Italy


PDF  


Aim. There is an increasing need for an appropriate and readily-available material to reconstruct large bone defects, one of the most significant problems in the dental and maxillo-facial fields. The in vitro study examines the effects of OSTEOPLANT® ANGIOSTAD, a product developed to increase osteoinductivity.
Methods. The product’s biological properties were assessed by examining: the viability of cultured bone-marrow mesenchymal stem cells (MSC) through the methylthiazol tetrazolium assay; transforming growth factor (TGF)-β release by these cells through the enzyme-linked immunosorbent assay (ELISA) and the migration capacity of MSC and endothelial cells, by the in vitro wound closure test and transwell-migration assay, respectively.
Results. OSTEOPLANT® ANGIOSTAD preserved MSC’s viability and improved their capacity to release TGF-β1. It also increased in vitro wound healing by MSC and migration of endothelial cells.
Conclusion. The results show that, since it increases the production by MSC of proangiogenic factors such as TGF-β and promotes endothelial cell migration, OSTEOPLANT® ANGIOSTAD may be an appropriate adjunct to accelerate the osteointegration of bone substitutes.

top of page

Publication History

Cite this article as

Corresponding author e-mail